

Abstract

Precision-cut tissue slices (PCTS) serve as an effective *ex vivo* model for studying human diseases. PCTS retain the complex tissue microenvironment including immune components and the extracellular matrix, rendering them a valuable tool for drug discovery.


We have successfully established *ex vivo* fibrosis and inflammation models using precision cut liver slices (PCLS) from rats. Following treatment with TGF- β for 24h, mRNA levels of IL-6, TNF- α , COL1A1, α -SMA, TGF- β 1, IL-1 β , etc., significantly increased compared to untreated PCLS controls. These changes were downregulated upon treatment with the anti-inflammatory drug dexamethasone or anti-fibrotic compounds such as SB525334 and Nintedanib.

Moreover, upon LPS induction, mRNA levels of IL-6, TNF- α , COL1A1, α -SMA, TGF- β 1, IL-1 β , IL-10, CTGF and iNOS significantly increased. Immune suppression drug like Tacrolimus and JAK inhibitor Baricitinib significantly decreased LPS-induced upregulation of these inflammation- and fibrosis-related genes.

PCTS treatment responses can be assessed using multiple readouts, including tissue viability, RNA and protein analyses, histology, and live-cell imaging. These readouts enhance PCTS's potential as a translational tool, bridging *in vitro* assay findings with *in vivo* efficacy. Ongoing studies showed promising results for advancing drug discovery.

Experimental design

Study Workflow



Results




Figure 1. Droplet Digital PCR (ddPCR) analysis of inflammation-related genes in LPS-induced inflammatory PCLS.




Figure 2. Droplet Digital PCR (ddPCR) analysis of pro-fibrotic genes in LPS-induced inflammatory PCLS.




Figure 3. Droplet Digital PCR (ddPCR) analysis of inflammation-related genes in TGF- β -induced fibrotic PCLS.

Effect of Nintedanib, Dexamethasone, and SB525334 on Fibrotic Gene Expression




Figure 4. Droplet Digital PCR (ddPCR) analysis of pro-fibrotic genes in TGF- β -induced fibrotic PCLS.

Summary

- An inflammatory and a fibrotic PCLS model were successfully established by LPS and TGF- β induction, respectively.
- In the inflammatory PCLS model, Baricitinib and Tacrolimus dose-dependently inhibited the mRNA expression of TNF- α , IL-1 β , IL-6, IL-10, iNOS, TGF- β 1, α -SMA, COL1A1, and CTGF.
- In the fibrotic PCLS model, Nintedanib and Dex decreased the mRNA expression of TNF- α , IL-6, IL-10, iNOS, TGF- β 1, α -SMA, COL1A1, and CTGF.

References

1. *Biochem Pharmacol* 2019 Nov;169(0):113633
2. *Biochim Biophys Acta Mol Basis Dis* 2020 Jan 1;1866(1):165582
3. *Toxicol Mech Methods* 2025 Jan;35(1):11-18
4. *Arch Toxicol* 2019 Dec;93(12):3549-3583
5. *Fluids Barriers CNS* 2013 Jan 21;10(1):6
6. *Mol Microbiol* 2022 Mar;117(3):578-588
7. *Methods Mol Biol* 2023;2664(0):123-134
8. *Nat Protoc* 2010 Sep;5(9):1540-51
9. *Front Immunol* 2022;13(0):1083248

